Inhaler Choice & Environment
Research type
Research Study
Full title
The impact of inhaler choice on climate change and personalised health
IRAS ID
304434
Contact name
Graham Lough
Contact email
Sponsor organisation
AstraZeneca
Duration of Study in the UK
0 years, 2 months, 0 days
Research summary
This study aims to:
Identify experience and preferences of patients and healthcare professionals (HCPs) of inhaler choice / change in relation to climate change and personalised healthcare (i.e., a patient’s autonomy in decision making about their own healthcare plan).
This research will provide opinion and preferences of patients and health care workers on:
• (a) Costs to environment: The impact of inhaler choice and switching inhaler delivery system on climate change, as well as short-term vs long-term solutions for reduction of impact.
The research will also gather information from patients on:
• (b) Personal impact: The impact of inhaler choice / changing medication that has affected their personalised healthcare plan and inhaler use.Two questionnaires will be distributed for data collection. Questionnaires are approved by REG scientific steering group before distribution. The surveys will recruit asthma / COPD patients prescribed inhaled medication and HCPs recruited through professional networks and patient associations. A live link to the survey on SurveyMonkey will be included.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
21/PR/1121
Date of REC Opinion
9 Sep 2021
REC opinion
Further Information Favourable Opinion